Boston Scientific Corporation vs Invesco Preferred ETF — how do they compare? Boston Scientific Corporation trades at $42.97 (market cap $66.37B), while Invesco Preferred ETF trades at $10.89. Which is the better fit depends on your goals.
| BSX | PGX | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | — |
52-Week High | $108.14 | $11.87 |
52-Week Low | $42.63 | $10.82 |
Enterprise Value | $75.94B | — |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
PGX trades at $10.83, down 0.18% with a bearish technical signal from moving averages. Recent news includes the sale of the Golden Sidewalk Project to Kenorland Exploration. Financial ratios are unavailable in the current data, limiting fundamental assessment. The stock faces negative sentiment from recent analyst coverage questioning its risk-reward profile.
The outlook remains cautious given bearish technical indicators and critical analyst commentary highlighting poor returns and limited downside protection. Investment opportunities appear constrained by structural concerns, while risks include participation in market selloffs and recovery rate uncertainties in debt instruments.
Trailing returns across standard periods
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →